Related Experiment Videos
[Multiple sclerosis: epidemiology, molecular pathology and therapy]
A J Steck1, N Schaeren-Wiemers
1Neurologische Universitätsklinik, Basel. steck@ubaclu.unibas.ch
Schweizerische Medizinische Wochenschrift
|December 22, 1999
Summary
Multiple sclerosis (MS) is an autoimmune central nervous system disease. Novel immunotherapies, including beta-interferon, show promise for managing MS symptoms and progression.
Area of Science:
- Neuroimmunology
- Central Nervous System Diseases
- Autoimmune Disorders
Context:
- Multiple sclerosis (MS) is characterized by inflammation and demyelination in the central nervous system.
- The disease arises from an autoimmune attack on cerebral white matter antigens.
- Pathogenesis involves T-cell migration and blood-brain barrier disruption.
Purpose:
- To explore the immunological underpinnings of multiple sclerosis.
- To review the role of B-cells, cytokines, and immune cells in MS pathogenesis.
- To highlight advancements in novel immunotherapies for MS.
Summary:
- MS involves autoimmune responses targeting central nervous system white matter.
- Both T-cells and B-cells, along with cytokines, contribute to demyelination.
- Recent immunological and biotechnological advances facilitate new therapeutic strategies.
Impact:
- Beta-interferon demonstrates efficacy in modulating the immune response in MS.
- These findings support the development of targeted immunotherapies for relapsing-remitting and secondary progressive MS.
- Advances offer new hope for patients with multiple sclerosis.